BIO-TECHNE Corp·4

Feb 5, 6:30 PM ET

Herr Amy E. 4

4 · BIO-TECHNE Corp · Filed Feb 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne (TECH) Director Amy Herr Exercises Options, Pays Tax Withholding

What Happened

  • Amy E. Herr, a director of Bio-Techne Corp (TECH), executed derivative transactions on 2026-02-03. She exercised/converted a derivative position that resulted in 38 shares acquired at $0.00 and also had 38 derivative shares disposed (conversion/settlement). Separately, 16 shares were disposed to satisfy a tax liability at $64.63 per share, generating $1,034 in withholding. Overall, the transactions result in a net decline of 16 shares held by Herr (38 acquired − 38 disposed − 16 withheld = −16).

Key Details

  • Date: 2026-02-03; Form 4 filed: 2026-02-05 (appears timely).
  • Transactions:
    • M (exercise/conversion): 38 shares acquired @ $0.00 (total $0).
    • F (payment of exercise price/tax withholding): 16 shares disposed @ $64.63 = $1,034.
    • M (exercise/conversion – recorded as disposed): 38 shares disposed @ $0.00.
  • Net effect: decrease of 16 shares.
  • Shares owned after the transaction: not specified in the provided excerpt of the filing.
  • Footnotes/notes: the F-coded disposition reflects tax withholding to satisfy withholding obligations. The filing includes multiple footnotes about vesting schedules for awards and options (see the filing for details).

Context

  • The pattern (exercise/conversion combined with a small number of shares withheld/surrendered) is typical of option/RSU vesting or conversion where shares are used to cover taxes rather than a market-directed sale. The cash proceeds reported were $1,034 from the 16-share tax withholding. These transactions are usually routine compensation-related actions and should not be interpreted as a market timing signal.

Insider Transaction Report

Form 4
Period: 2026-02-03
Herr Amy E.
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-03+382,192 total(indirect: By significant other)
  • Tax Payment

    Common Stock

    2026-02-03$64.63/sh16$1,0342,176 total(indirect: By significant other)
  • Exercise/Conversion

    Restricted Stock Units

    [F7][F10]
    2026-02-033877 total(indirect: By significant other)
    Common Stock (38 underlying)
Holdings
  • Common Stock

    2,680
  • Stock Option (Right to Buy)

    Exercise: $72.05From: 2025-10-24Exp: 2035-02-03Common Stock (2,415 underlying)
    2,415
  • Stock Option (Right to Buy)

    [F1]
    Exercise: $60.96Exp: 2035-10-30Common Stock (3,777 underlying)
    3,777
  • Stock Option (Right to Buy)

    [F2]
    (indirect: By significant other)
    Exercise: $47.60Exp: 2026-08-07Common Stock (6,636 underlying)
    6,636
  • Stock Option (Right to Buy)

    [F2]
    (indirect: By significant other)
    Exercise: $66.97Exp: 2027-08-05Common Stock (4,472 underlying)
    4,472
  • Stock Option (Right to Buy)

    [F2]
    (indirect: By significant other)
    Exercise: $120.46Exp: 2028-08-06Common Stock (2,076 underlying)
    2,076
  • Stock Option (Right to Buy)

    [F3]
    (indirect: By significant other)
    Exercise: $94.52Exp: 2029-08-15Common Stock (2,104 underlying)
    2,104
  • Stock Option (Right to Buy)

    [F4]
    (indirect: By significant other)
    Exercise: $84.61Exp: 2030-08-15Common Stock (1,084 underlying)
    1,084
  • Stock Option (Right to Buy)

    [F5]
    (indirect: By significant other)
    Exercise: $74.91Exp: 2034-08-15Common Stock (1,468 underlying)
    1,468
  • Stock Option (Right to Buy)

    [F6]
    (indirect: By significant other)
    Exercise: $72.05Exp: 2035-02-03Common Stock (344 underlying)
    344
  • Restricted Stock Units

    [F7][F8]
    (indirect: By significant other)
    Common Stock (118 underlying)
    118
  • Restricted Stock Units

    [F7][F9]
    (indirect: By significant other)
    Common Stock (320 underlying)
    320
  • Restricted Stock Units

    [F7][F11]
    (indirect: By significant other)
    Common Stock (932 underlying)
    932
  • Stock Option (Right to Buy)

    [F12]
    (indirect: By significant other)
    Exercise: $53.60Exp: 2035-08-15Common Stock (2,735 underlying)
    2,735
Footnotes (12)
  • [F1]This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
  • [F10]38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
  • [F11]311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
  • [F12]Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
  • [F2]Fully vested.
  • [F3]Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
  • [F4]Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
  • [F5]Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F6]Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
  • [F7]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F8]118 restricted stock units vest on 8/15/2026.
  • [F9]160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed|2026-02-05

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES